📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
1 analysed today
FollowTelegram
1
Today
151,861
All-time analysed
43,535
Positive
6,743
Negative
92,746
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
846 announcements match the current filters (relevance ≥ 5).
Biocon launches Liraglutide (gVictoza®) in Netherlands
Biocon Limited has launched its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. Liraglutide was approved for medical use in the European Union in 2009.
Key Highlights
Biocon launched Liraglutide in the Netherlands on December 15, 2025.
Liraglutide will be marketed as Diavorin® for diabetes.
Liraglutide will be marketed as Vobexoryn® for chronic weight management.
Liraglutide was approved for medical use in the European Union in 2009.
👀 What to Watch
This launch in the Netherlands is a positive step for Biocon, indicating expansion in the European market; investors should monitor the sales performance of Diavorin® and Vobexoryn® in the coming quarters.
Biocon Biologics to Commercialize Biosimilar Aflibercept Worldwide
Biocon Biologics has signed a settlement and license agreement to commercialize biosimilar Aflibercept (YESAFILI) worldwide. This agreement with Regeneron and Bayer covers Europe and the rest of the world, following a previous settlement for the US and Canada. YESAFILI is a VEGF inhibitor used for ophthalmology conditions. The company plans to launch YESAFILI in the UK in January 2026 and in other settled countries by March 2026 or earlier.
Key Highlights
Biocon Biologics will commercialize biosimilar Aflibercept (40mg/ml) worldwide.
YESAFILI launch in the United Kingdom is planned for January 2026.
YESAFILI launch in other settled countries is planned for March 2026 or earlier.
Biocon Biologics has commercialized 10 biosimilars across 120+ countries.
👀 What to Watch
This agreement expands Biocon Biologics' global presence in the ophthalmology therapeutic area. Investors should monitor the launch and market uptake of YESAFILI in 2026.
IFB Industries Incorporates Swiss Step-Down Subsidiary Schmid Automotive & Appliances GmbH
IFB Industries' wholly-owned subsidiary, Global Automotive & Appliances Pte. Ltd. (GAAL), has incorporated a new step-down subsidiary in Switzerland named Schmid Automotive & Appliances GmbH. The new entity has a paid-up share capital of CHF 20,000, consisting of 2,000 shares at CHF 10 each. This subsidiary is established to focus on the design, development, and planning of machine tools and fine blanking tools to enhance the company's overall engineering capabilities. As a newly formed entity, it has not yet commenced business operations and reports nil turnover.
Key Highlights
Incorporation of Schmid Automotive & Appliances GmbH in Switzerland on December 10, 2025.
100% ownership held by IFB's subsidiary GAAL, making it a step-down subsidiary of IFB Industries.
Initial paid-up share capital of CHF 20,000 (2,000 shares of CHF 10 each).
Strategic focus on R&D and engineering for machine tools and fine blanking tools.
The entity is currently in the pre-operational stage with no reported turnover yet.
👀 What to Watch
Investors should monitor how this Swiss-based engineering hub contributes to IFB's product development and technical capabilities in the long term. While the immediate financial impact is negligible, it strengthens the company's strategic positioning in the automotive and appliance industries.
SBIN to invest ₹1 Crore in Indian Digital Payment Intelligence Corporation
State Bank of India (SBIN) has received RBI approval to establish a Section 8 company under the Companies Act, 2013. SBIN will subscribe to 1,00,00,000 (One crore) equity shares of Indian Digital Payment Intelligence Corporation (IDPIC) as the initial promoter. The investment will be at a face value of ₹10 per share, acquiring a 50% stake in the company. This move signifies SBIN's strategic interest in the digital payment intelligence space.
Key Highlights
RBI approved SBIN to establish a Section 8 company.
SBIN to invest ₹1 Crore in IDPIC.
SBIN will acquire a 50% stake in IDPIC.
The face value of each share is ₹10.
👀 What to Watch
Investors should monitor the performance of this new venture and its impact on SBIN's overall digital strategy. Keep an eye on further developments related to IDPIC and its role in the digital payment ecosystem.
S&P Global Places Biocon Biologics on Positive CreditWatch; Debt to Drop to ₹120 Billion
S&P Global Ratings has placed Biocon Biologics on 'CreditWatch Positive' following a major restructuring plan to make it a 100% subsidiary of Biocon Limited. The company aims to reduce its adjusted debt significantly from INR 248 billion in March 2025 to approximately INR 120 billion by March 2026. This reduction will be driven by swapping $1 billion in debt-like CCPS held by Viatris for equity and cash, alongside a planned INR 45 billion fresh equity issuance. The move simplifies the capital structure and eliminates minority put options that were previously viewed as debt-like obligations.
Key Highlights
S&P Global placed 'BB' rating on CreditWatch Positive, signaling a potential upgrade within 60-90 days.
Adjusted debt is projected to fall by over 50% to INR 120 billion by the end of FY26.
Biocon to acquire the remaining 25% stake in Biocon Biologics from minority investors including Viatris and Serum Institute.
Viatris' $1 billion CCPS will be settled through $415 million in Biocon equity and $400 million in cash.
The cash component for the transaction is intended to be funded via a fresh INR 45 billion equity raise.
👀 What to Watch
Investors should view this as a major positive for the balance sheet as it significantly reduces leverage and simplifies the corporate structure. Key monitorables include the successful execution of the INR 45 billion equity fundraise and the final resolution of the CreditWatch by S&P.
Tasty Bite Q2 FY25 PAT Rises 24% YoY to ₹96.1 Million; Revenue Up 14.6%
Tasty Bite Eatables Limited reported a strong performance for the quarter ended September 30, 2025, with revenue from operations increasing 14.6% YoY to ₹1,328.67 million. Net profit for the quarter grew significantly by 23.9% YoY to ₹96.14 million, up from ₹77.58 million in the previous year. For the first half of FY25, the company achieved a PAT of ₹188.34 million compared to ₹153.27 million in H1 FY24. Additionally, the company strengthened its governance by appointing KPMG as internal auditors and adding Hans Bakker to the Board.
Key Highlights
Revenue from operations grew 14.6% YoY to ₹1,328.67 million in Q2 FY25.
Net Profit (PAT) increased by 23.9% YoY to ₹96.14 million for the quarter.
Earnings Per Share (EPS) rose to ₹37.47 from ₹30.23 in the corresponding quarter last year.
Cash and cash equivalents surged to ₹577.64 million as of September 30, 2025, from ₹153.48 million in March 2025.
H1 FY25 total income reached ₹2,592.17 million, a 10.9% increase over H1 FY24.
👀 What to Watch
Investors should view the consistent top-line and bottom-line growth positively, alongside the significantly improved cash position. The stock remains a key play in the 'Prepared Foods' segment, though monitoring raw material price volatility is advised.
MobiKwik: Top 3 Fastest-Growing UPI App, 3x YoY Growth in Oct '25
MobiKwik has announced that it is among the top 3 fastest-growing UPI apps in India in Q2FY26. The company's UPI transactions surged 38% QoQ, and UPI GMV increased by 28%. MobiKwik also registered 3x YoY UPI growth in October 2025. Pocket UPI is emerging as a key driver of MobiKwik’s UPI scale, allowing users to make UPI payments directly from their MobiKwik Wallet.
Key Highlights
UPI transactions surged 38% QoQ
UPI GMV increased by 28%
Registered 3x YoY UPI growth in October 2025
MobiKwik has a 19% market share of the PPI wallet gross transaction value (GTV) as of September 2025
Serving 183.5 Mn+ registered users and 4.71 Mn+ merchants
👀 What to Watch
Investors should monitor MobiKwik's ability to sustain this growth and improve profitability. Watch for further updates on user acquisition and engagement metrics.
SAT Upholds IRDAI Order for Transfer of Sahara Life Assets and Liabilities to SBI Life
The Securities Appellate Tribunal (SAT) has dismissed an appeal by Sahara India Life Insurance (SILIC) against a 2023 IRDAI order. This ruling mandates the immediate transfer of all SILIC policyholder-related assets and liabilities to SBI Life Insurance Company Limited. The decision, received on December 10, 2025, concludes a legal challenge to the IRDAI's directive aimed at protecting Sahara's policyholders. This transfer will result in an inorganic expansion of SBI Life's policyholder base and assets under management.
Key Highlights
SAT dismissed the appeal filed by Sahara India Life Insurance against the IRDAI order dated June 2, 2023.
SBI Life is directed to immediately take over all policyholder-related assets and liabilities of SILIC.
The order follows a multi-year regulatory effort to safeguard the interests of Sahara Life policyholders.
The transfer is expected to increase SBI Life's market share and total policyholder liabilities under management.
👀 What to Watch
Investors should view this as a positive development that reinforces SBI Life's role as a stable market leader. Monitor for upcoming disclosures regarding the specific financial impact on the company's Embedded Value and integration costs.
SBI Receives RBI Approval to Set Up Digital Payments Intelligence Platform
State Bank of India (SBI) has received approval from the Reserve Bank of India (RBI) to establish a Section 8 company named Indian Digital Payment Intelligence Corporation. This new entity will focus on creating a Digital Payments Intelligence Platform to enhance the security and monitoring of digital transactions. The Department of Financial Services has granted a specific exemption allowing SBI to hold more than 30% of the paid-up share capital in this company. This exemption from Section 19(2) of the Banking Regulation Act is currently valid until October 16, 2026.
Key Highlights
RBI approval granted to establish 'Indian Digital Payment Intelligence Corporation' as a Section 8 company.
Exemption received from Section 19(2) of the Banking Regulation Act, 1949, to hold over 30% stake.
The shareholding exemption for the proposed entity is valid until October 16, 2026.
The platform is designed to provide intelligence and risk management for the digital payments ecosystem.
The initiative aligns with national goals to reduce digital payment frauds and improve transaction security.
👀 What to Watch
Investors should view this as a strategic move to strengthen SBI's digital infrastructure and risk management capabilities. While not a direct profit driver, it reinforces SBI's leadership in the digital banking space and long-term operational stability.
Biocon's debt instruments rated by India Ratings
India Ratings has assigned 'IND AA+/Stable/IND A1+' to Biocon's bank loan facilities of INR 5,500 million and 'IND A1+' to proposed commercial paper of INR 8,000 million. The agency has also affirmed 'IND AA+/Stable/ IND A1+' for existing bank loan facilities of INR 4,500 million and 'IND A1+' for proposed commercial paper of INR 12,000 million. The rating on non-convertible debentures of INR 10,700 million has been withdrawn as the instrument has been paid in full. These ratings reflect India Ratings' assessment of Biocon's creditworthiness.
Key Highlights
INR 5,500 million bank loan facilities assigned IND AA+/Stable/IND A1+ rating
INR 8,000 million proposed commercial paper assigned IND A1+ rating
INR 4,500 million bank loan facilities affirmed at IND AA+/Stable/ IND A1+
INR 12,000 million proposed commercial paper affirmed at IND A1+
INR 10,700 million non convertible debenture rating withdrawn
👀 What to Watch
Investors should monitor Biocon's debt levels and credit ratings for any changes. The affirmed and assigned ratings indicate a stable outlook for the company's debt obligations.
Biocon to Consolidate 100% Stake in Biocon Biologics via $1.17 Billion Deal
Biocon Limited has announced a major consolidation plan to acquire the remaining 23.3% minority stake in Biocon Biologics, making it a 100% subsidiary. The transaction involves a $773 million share swap (171.3 million shares at ₹405.78 each) and a $400 million cash payment to Viatris. This move is designed to simplify the corporate structure, eliminate the holding company discount, and improve financial metrics, with a proforma Net Debt/EBITDA ratio of 2.5x. The company expects the transaction to be completed by Q4 FY2026, following a shareholder vote on December 31, 2025.
Key Highlights
Acquisition of 23.3% minority stake from Viatris, Serum Institute, Tata Capital, and True North.
Total consideration includes $773M in equity shares and $400M in cash funded via QIP or bridge loans.
Consolidation expected to generate annual interest savings of ₹300 crore.
Proforma Net Debt/EBITDA reduced to 2.5x from 4.3x in FY23 through deleveraging and EBITDA growth.
Targeting transaction completion by Q4 FY2026 with a long-stop date of March 31, 2026.
👀 What to Watch
Investors should look favorably on this consolidation as it simplifies the group structure and removes the holding company discount. Monitor the upcoming EGM on December 31 and the successful execution of the $400M cash funding through a QIP or rights issue.
SBI Cards Appoints Former RBI Executive Director Parvathy Vairava Sundaram as Independent Director
SBI Cards and Payment Services Limited has appointed Smt. Parvathy Vairava Sundaram as an Additional Independent Director for a three-year term effective December 9, 2025. Smt. Sundaram is a former Executive Director of the Reserve Bank of India (RBI) with significant experience in central banking regulation and supervision. Her background includes overseeing the 2015-17 Asset Quality Review and the migration of banks to Risk Based Supervision. This appointment is expected to strengthen the company's board oversight and regulatory compliance framework.
Key Highlights
Appointment of Smt. Parvathy Vairava Sundaram as Independent Director for a 3-year term ending December 2028.
Appointee previously served as Executive Director at the RBI and superannuated in November 2019.
She led critical regulatory initiatives including the 2015-17 Asset Quality Review and revised PCA guidelines.
Currently a member of the Standing External Advisory Committee for bank licensing in India.
The appointment is subject to the approval of the company's shareholders.
👀 What to Watch
Investors should view this as a positive corporate governance development, as the addition of a high-profile former regulator enhances board-level risk management. No immediate portfolio changes are necessary based on this appointment.
Rubicon Research Shareholders Approve Promote Agreement and ESOP Ratifications
Rubicon Research Limited has successfully passed six key resolutions via postal ballot, including the approval of a Promote Agreement and the ratification of ESOP schemes from 2019 and 2022. All resolutions received the requisite majority, although Resolution 1 (Promote Agreement) and Resolution 2 (Shareholder Rights) saw notable dissent from public institutions at 26.27% and 38.63% respectively. The ESOP ratifications, covering both the company and its subsidiaries, passed with over 95% support. These approvals are critical for the company's post-listing governance and long-term incentive structures.
Key Highlights
Shareholders approved the Promote Agreement dated July 30, 2024, with 88.81% of total votes in favour.
Ratification of Investor and Management Shareholders rights passed with a 93.37% overall majority.
ESOP 2019 and ESOP 2022 schemes for the company and its subsidiaries were ratified with approximately 95.18% support.
Public institutions showed significant dissent on Resolution 2, with 38.63% of their votes cast against the ratification of shareholder rights.
👀 What to Watch
Investors should monitor the impact of the Promote Agreement on future earnings and observe if the high institutional dissent on shareholder rights leads to any governance adjustments.
CONCORDBIO: CFO Lalit Sethi Resigns, Effective January 5, 2026
Concord Biotech Limited announced the resignation of its Chief Financial Officer (CFO), Mr. Lalit Sethi, effective January 5, 2026. Mr. Sethi's resignation is due to personal reasons and early retirement as he approaches age 59. He has submitted his intention to retire early via a letter dated December 8, 2025. The company has ensured a seamless transition, including a complete handover of financial statements and compliance documentation.
Key Highlights
Lalit Sethi, CFO, will retire effective January 5, 2026
Resignation is due to personal reasons and early retirement at age 59
Trading window closed from December 8, 2025, until 48 hours after the announcement
👀 What to Watch
Investors should monitor the transition and any potential impact on the company's financial strategy. While the resignation appears amicable, keep an eye on the appointment of the new CFO and their vision for the company.
Biocon to Issue 17.13 Cr Shares at ₹405.78 and Raise Investment Limits to ₹20,000 Cr
Biocon has convened an Extra-Ordinary General Meeting (EGM) on December 31, 2025, to seek approval for significant capital restructuring. The company proposes to issue up to 17,12,79,553 equity shares on a preferential basis at ₹405.78 per share for consideration other than cash. Additionally, it seeks to increase its authorized share capital to ₹900 crore and significantly expand its investment and loan limits under Section 186 to ₹20,000 crore. These moves suggest a major upcoming acquisition or strategic asset integration.
Key Highlights
Preferential issuance of up to 17.13 crore equity shares at a fixed price of ₹405.78 per share
Proposed increase in Authorized Share Capital from ₹700 crore to ₹900 crore
Expansion of Section 186 limits for loans, guarantees, and investments to ₹20,000 crore
The share issuance is for 'consideration other than cash', indicating a potential swap or acquisition
EGM scheduled for December 31, 2025, with a voting cut-off date of December 24, 2025
👀 What to Watch
Investors should closely monitor the specific details of the asset or entity being acquired in exchange for the 17.13 crore shares, as this represents significant equity dilution. The pricing of ₹405.78 serves as a key valuation benchmark for the stock in the near term.
Biocon to fully integrate Biocon Biologics via ₹6,950 Cr share swap and ₹4,500 Cr fundraise
Biocon Limited has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from Mylan, Serum Institute, Tata Capital, and Activ Pine to simplify its corporate structure. The transaction involves a preferential issue of 17.12 crore shares valued at approximately ₹6,950 crore as a share swap and a separate fundraise of up to ₹4,500 crore for cash consideration. Additionally, the company will issue Commercial Papers worth ₹1,800 crore for interim financing needs. This integration aims to create a larger balance sheet and a unified capital allocation strategy to maximize stakeholder value.
Key Highlights
Acquisition of 40,55,86,862 shares of Biocon Biologics Limited to achieve full integration and operational synergies.
Issuance of 17,12,79,553 equity shares on a preferential basis for a total value of up to ₹6,950 crore.
Approved a fundraise of up to ₹4,500 crore via QIP or Rights Issue primarily to fund cash payments to Mylan Inc.
Issuance of Commercial Papers up to ₹1,800 crore to manage interim cash requirements for the Mylan transaction.
Increase in authorized share capital from ₹700 crore to ₹900 crore to facilitate the new share issuances.
👀 What to Watch
Investors should view this as a significant long-term strategic consolidation that simplifies the group structure, though they should monitor the potential equity dilution from the preferential issue and QIP.
Biocon to raise ₹4,500 Cr, acquires Biocon Biologics shares
Biocon Limited's board approved raising up to ₹4,500 Crores through various means to fund the cash consideration payable to Mylan. The company will also acquire equity shares of Biocon Biologics Limited (BBL) from multiple shareholders, including Mylan, Serum Institute, Tata Capital, and Activ Pine. As part of this acquisition, Biocon will issue 17,12,79,553 equity shares on a preferential basis, amounting to ₹6,950 Crores, for consideration other than cash. The board also approved an increase in authorized share capital from ₹700 Crores to ₹900 Crores.
Key Highlights
Raising funds up to ₹4,500 Crores.
Issuance of 17,12,79,553 equity shares on a preferential basis.
Increase in authorized share capital from ₹700 Crores to ₹900 Crores.
Acquisition of 40,55,86,862 shares of Biocon Biologics Limited (BBL).
Issuance of Commercial Papers for an amount up to ₹1,800 Crores
👀 What to Watch
Investors should closely monitor the progress of the fund-raising and acquisition of Biocon Biologics shares, as these actions could significantly impact the company's financial structure and future growth prospects. Attend the Extra-Ordinary General Meeting on December 31, 2025 to vote on these proposals.
Biocon to Consolidate BBL Ownership via ₹6,950 Cr Share Swap and ₹4,500 Cr Fundraise
Biocon Limited has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from key partners including Mylan, Serum Institute, and Tata Capital. The deal involves a preferential issuance of 17.13 crore shares worth up to ₹6,950 crore via a share swap and an additional fundraise of ₹4,500 crore to cover cash considerations. This strategic move aims to simplify the corporate structure, unify capital allocation, and fully integrate BBL's biosimilar business into the parent company.
Key Highlights
Approved the issuance of 17,12,79,553 equity shares on a preferential basis for a total value of up to ₹6,950 crore.
Planned fundraise of up to ₹4,500 crore through QIP, Rights Issue, or other securities to fund cash payments to Mylan.
Authorized share capital increased from ₹700 crore to ₹900 crore to facilitate the new share issuances.
Approved issuance of Commercial Papers up to ₹1,800 crore for interim cash requirements related to the Mylan transaction.
The consolidation aims to achieve operational synergies and a larger balance sheet by integrating BBL's global biosimilar portfolio.
👀 What to Watch
Investors should view this as a major strategic consolidation that simplifies the group structure, though they must account for the equity dilution from the 17.13 crore new shares. Monitor the pricing of the ₹4,500 crore fundraise and the upcoming EGM on December 31, 2025, for final shareholder approvals.
Biocon to Fully Integrate Biocon Biologics via ₹6,950 Cr Share Swap and ₹4,500 Cr Fundraise
Biocon Limited has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from partners including Mylan, Serum Institute, and Tata Capital. The transaction involves a preferential share issuance of 17.13 crore shares worth up to ₹6,950 Crores as a swap and a cash payout to Mylan. To fund the cash component, Biocon plans to raise up to ₹4,500 Crores through QIP or other instruments. This strategic move aims to simplify the corporate structure and consolidate the balance sheet for better capital allocation.
Key Highlights
Acquisition of 40.56 crore shares of Biocon Biologics to achieve full integration and ownership.
Preferential issuance of 17,12,79,553 equity shares worth up to ₹6,950 Crores to selling shareholders.
Proposed fundraise of up to ₹4,500 Crores to finance the cash consideration payable to Mylan Inc.
Authorized share capital increased from ₹700 Crores to ₹900 Crores to facilitate the transaction.
Interim funding of ₹1,800 Crores approved via Commercial Papers to bridge the cash requirement.
👀 What to Watch
Investors should monitor the pricing of the ₹4,500 Cr fundraise and the resulting equity dilution, but the long-term consolidation of the biologics business is a significant positive for structural efficiency. The integration is expected to unlock operational synergies and provide a unified capital allocation strategy.
Biocon to consolidate Biocon Biologics; Analyst call on Dec 8, 2025
Biocon Limited will hold an analyst call on December 8, 2025, to discuss Biocon Biologics Limited’s integration with Biocon Limited. The acquisition of minority shareholder stake of 23.3% in Biocon Biologics will be funded through issuance of 171.3 MM equity shares in Biocon Limited and cash consideration of $400MM. The share swap ratio is 61.70 shares of Biocon for every 100 shares of BBL for BBL Shareholders. The transaction is expected to be completed by Q4 FY2026.
Key Highlights
Acquisition of minority stake in Biocon Biologics to be funded through issuance of 171.3 MM equity shares
Cash consideration of $400MM to be paid for acquisition of minority stake
Share swap ratio of 61.70 for BBL shareholders
BL share price considered for share swap at ₹ 405.78 per share
Biocon Ltd has a 52.4% stake in Syngene
👀 What to Watch
Investors should review the presentation and listen to the analyst call on December 8, 2025, to understand the strategic rationale and financial implications of the consolidation. Monitor regulatory approvals and shareholder consent for the transaction.
